Management of HBV infection in Japan

Hepatology Research

Volumn 37, Issue SUPPL. 1, 2007, Pages

  Minami, Masahito ^a,b   Okanoue, Takeshi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Genotype; HBV; Interferon; Lamivudine

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

AGE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; JAPAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MONOTHERAPY; NONHUMAN; PILOT STUDY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS CARRIER; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 34447644610     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00109.x     Document Type: Conference Paper

References (9)

1. Okanoue T, Minami M. Update of research and management of hepatitis B. J Gastroenterol 2006; 41: 107-18.
2. Lok ASF, McMahon BJ. Chronic hepatitis B: Update of recommendations. Hepatology 2004; 39: 857-61.
3. de Franchis R, Hadengue A, Lau G et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39 (Suppl. 1): S3-25.
4. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
5. van Nunen AB, Hansen BE, Suh DJ et al. Durability of HBe Ag seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-4.
6. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
7. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
8. Chan HL, Hui AY, Wong VW, Chim AM, Wong M, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41: 1357-64.
9. Serfaty L, Thabut D, Zoulim F et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study. Hepatology 2001; 34: 573-7.